Aoife Brennan
, President and CEO, Climb Bio
Aoife is currently President and CEO of Climb Bio (NASDAQ: CLYM), a clinical stage biotech company focused on developing treatments for immune-mediated diseases. She has led the company through the acquisition of Tenet Medicines by Eliem Therapeutics in July 2024 and the subsequent rebranding and full organizational rebuild as Climb Bio. She brings to Climb Bio over 20 years of experience leading drug development organizations across a range of stages and therapeutic areas having most recently served as the President and Chief Executive Officer of Synlogic, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to Synlogic, Aoife served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc., where she led the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as other early-stage programs. She has served as a director and advisor to several public and private biotech companies and including Ra Pharmaceuticals, Inc. (acquired by UCB), and is currently a member of the BOD of Cerevance, LLC and Xilio Therapeutics.
In addition to her roles in biotech, she has also contributed to several civic and non-profit organizations and is a board member of the Critical Path Institute a public-private partnership with the US Food and Drug Administration (FDA) dedicated to improving drug development.
Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. She is fellowship trained in internal medicine, endocrinology and metabolism.
